Skip to main content
Erschienen in: Medical Oncology 1/2011

01.12.2011 | Original Paper

Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients

verfasst von: Ellen B. Kossoff, Nuttapong Ngamphaiboon, Thomas J. Laudico, Tracey L. O’Connor

Erschienen in: Medical Oncology | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Ixabepilone 40 mg/m2 administered on an every 3-week schedule is approved for use in metastatic breast cancer (MBC) as monotherapy, or in combination with capecitabine in anthracycline/taxane resistant tumors. Because the mechanism of action and toxicity profile is similar to the taxanes, it has been suggested that weekly administration (15–20 mg/m2 on days 1, 8, 15 for 28 days/cycle) may provide a therapeutic advantage while minimizing toxicity. We report 24 MBC patients treated with weekly ixabepilone. Demographics, ER/PR/HER-2/neu, ECOG performance status (PS), sites of metastatic disease, lines of previous therapy, dosage, treatment duration, dose reductions/interruptions, hematologic/non-hematologic toxicities, growth factor use, reasons for discontinuation, time to progression (TTP), and response rate were recorded. Median age was 61 years (33–79). 0–1 ECOG PS was 54%. Sixty-seven percent of patients received ≥4 previous chemotherapy regimens. Median treatment duration was 1.4 months (0.5–10.8). Median dose was 16 mg/m2 (15–20). In 37.5% of patients, the dose was held due to toxicities with median missed dose of 2. Partial response and stable disease were 4 and 48%. Median TTP was 2.1 months (0.9–16.4). Majority of patients discontinued therapy due to disease progression (84%). Grade 3–4 neutropenia and neuropathy were 4% and 8%. It is not yet clear whether the weekly administration of ixabepilone impacts the risk/benefit profile. There are clinical data to suggest that weekly ixabepilone is efficacious and tolerable. Upcoming clinical trials will continue to inform the question. Our data suggest that weekly ixabepilone is well tolerated with a manageable side-effect profile in this small, heavily pretreated population.
Literatur
1.
Zurück zum Zitat Ixempra Kit (ixabepilone) prescribing information. Princeton: NJ; 2009 (Bristol-Myers Squibb Company). Ixempra Kit (ixabepilone) prescribing information. Princeton: NJ; 2009 (Bristol-Myers Squibb Company).
2.
Zurück zum Zitat Thomas ES, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210–7.PubMedCrossRef Thomas ES, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210–7.PubMedCrossRef
3.
Zurück zum Zitat Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2008;26(13):2223.PubMedCrossRef Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2008;26(13):2223.PubMedCrossRef
4.
Zurück zum Zitat Bollag DM, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–33.PubMed Bollag DM, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–33.PubMed
5.
Zurück zum Zitat Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2002;2(1):1–17.PubMedCrossRef Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2002;2(1):1–17.PubMedCrossRef
6.
Zurück zum Zitat Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents. 2002;2(1):123–48.PubMedCrossRef Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents. 2002;2(1):123–48.PubMedCrossRef
7.
Zurück zum Zitat Heinz DW, Schubert WD, Hofle G. Much anticipated–the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed Engl. 2005;44(9):1298–301.PubMedCrossRef Heinz DW, Schubert WD, Hofle G. Much anticipated–the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed Engl. 2005;44(9):1298–301.PubMedCrossRef
8.
Zurück zum Zitat Lee FY, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009;63(2):201–12.PubMedCrossRef Lee FY, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009;63(2):201–12.PubMedCrossRef
9.
Zurück zum Zitat Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist. 2008;13(12):1207–23.PubMedCrossRef Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist. 2008;13(12):1207–23.PubMedCrossRef
10.
Zurück zum Zitat Hortobagyi GN, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010;122(2):409–18.PubMedCrossRef Hortobagyi GN, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010;122(2):409–18.PubMedCrossRef
11.
Zurück zum Zitat Sparano JA, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256–63.PubMedCrossRef Sparano JA, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256–63.PubMedCrossRef
12.
Zurück zum Zitat Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.PubMedCrossRef Miller K, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.PubMedCrossRef
13.
Zurück zum Zitat Seidman AD, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26(10):1642–9.PubMedCrossRef Seidman AD, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26(10):1642–9.PubMedCrossRef
14.
Zurück zum Zitat Kossoff E. Alternative dosing schedules and administration updates for ixabepilone. J Oncol Pharm Pract. 2010. Kossoff E. Alternative dosing schedules and administration updates for ixabepilone. J Oncol Pharm Pract. 2010.
15.
Zurück zum Zitat Awada A, et al. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother Pharmacol. 2009;63(3):417–25.PubMedCrossRef Awada A, et al. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother Pharmacol. 2009;63(3):417–25.PubMedCrossRef
16.
Zurück zum Zitat Moulder S, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010;119(3):663–71.PubMedCrossRef Moulder S, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010;119(3):663–71.PubMedCrossRef
17.
Zurück zum Zitat Rugo HS, et al. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab(ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J Clin Oncol. 2010;28(15s):abstract#1040. Rugo HS, et al. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab(ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J Clin Oncol. 2010;28(15s):abstract#1040.
18.
Zurück zum Zitat O’Connor OA, et al. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2008;143(2):201–9.PubMedCrossRef O’Connor OA, et al. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2008;143(2):201–9.PubMedCrossRef
19.
Zurück zum Zitat Wilding G, Chen Y, DiPaola RP, Carducci MA, Liu G. E3803: update results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol 2008;26(suppl):abstract#5070. Wilding G, Chen Y, DiPaola RP, Carducci MA, Liu G. E3803: update results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol 2008;26(suppl):abstract#5070.
20.
Zurück zum Zitat Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008;19(5):977–83.PubMedCrossRef Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008;19(5):977–83.PubMedCrossRef
21.
Zurück zum Zitat Ott PA, et al. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One. 2010;5(1):e8714.PubMedCrossRef Ott PA, et al. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One. 2010;5(1):e8714.PubMedCrossRef
22.
Zurück zum Zitat De Geest K, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149–53.PubMedCrossRef De Geest K, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149–53.PubMedCrossRef
23.
Zurück zum Zitat Perez EA, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407–14.PubMedCrossRef Perez EA, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407–14.PubMedCrossRef
24.
Zurück zum Zitat Thomas E, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25(23):3399–406.PubMedCrossRef Thomas E, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25(23):3399–406.PubMedCrossRef
26.
Zurück zum Zitat Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef
Metadaten
Titel
Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients
verfasst von
Ellen B. Kossoff
Nuttapong Ngamphaiboon
Thomas J. Laudico
Tracey L. O’Connor
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe Sonderheft 1/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9726-6

Weitere Artikel der Sonderheft 1/2011

Medical Oncology 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.